Synthesis and Antimicrobial Resistant Modulatory Activity of 2,4-Dinitrophenylhydrazone Derivatives as Agents against Some ESKAPE Human Pathogens

Table 2

Antimicrobial activity of the compounds against the panel of organisms.

Test organisms	Minimum inhibitory concentrations (µM) of the phenylhydrazones
	BP1	BA2	MHB3	VL4	SA5	DHB6	CPR	FLZ
Staphylococcus aureus (+)	>552	699	>662	602	662	>628	4.72	Nd
Streptococcus pneumoniae (+)	552	699	>662	300.96	165	314	2.36	Nd
Escherichia coli (−)	>552	699	>662	602	662	628	4.72	Nd
Pseudomonas aeruginosa (−)	>552	>699	>662	602	662	628	2.36	Nd
Klebsiella pneumoniae (−)	138	699	>662	602	331	314	2.36	Nd
Candida albicans	552	699	>562	602	662	314	Nd	327

BP1 [benzophenone derivative], BA2 [benzaldehyde derivative], MHB3 [m-hydroxy benzaldehyde], VL4 [vanillin derivative], SA5 [salicylaldehyde derivative], DHB6 [2, 4-dihydroxybenzaldehyde derivative]; standard antibiotics: CPR [ciprofloxacin] and FLZ [fluconazole]. Nd [not determined]. All tests were carried out in triplicate (n = 3).